Primary biliary cholangitis (PBC) is a chronic progressive autoimmune disorder characterized by small non-purulent ...

Elafibranor (Iqirvo) was well tolerated and led to sustained improvements in liver enzyme levels and itch severity through 28 weeks in patients with primary sclerosing cholangitis (PSC), according to ...

Findings indicate blood group A elevates the risk of primary biliary cholangitis, suggesting ABO group analysis could aid in ...

Data expected H2 2026Rare liver disease with no approved treatment, typically concurrent with Inflammatory Bowel Disease (IBD)Second YAQ001 ...

The lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes ...

The mechanisms responsible for abdominal pain in primary sclerosing cholangitis are not fully understood. To assess gallbladder emptying and its association with cholecystitis and abdominal pain in ...

Phase 1 ex-US trial achieved primary objective of predictable pharmacokinetic profiling with favorable safety and tolerability Company expects to engage FDA on Phase 2 trial design and expects topline ...

The soccer host began posting updates about his health after viewers reached out saying they were worried about his eyes, ...

FOSTER CITY, Calif., October 23, 2025--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new research that reinforces its commitment to advancing innovation for people living with ...

Chronic liver disease (CLD) and its advanced stage, cirrhosis, represent a significant global health burden, with portal ...

This year’s scientific meeting had the highest patient attendance in AASLD history. The patients' message: stigma delays ...

BRIDGEWATER, NJ / ACCESSWIRE / October 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic ...